Disease · MONDO_0040679
Trials286
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 286
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | 1,213 | 2023-12-13 | Urothelial Carcinoma | ATEZOLIZUMAB, CARBOPLATIN, CISPLATIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT02853305 | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | Phase 3 | 1,010 | 2021-05-20 | Urothelial Carcinoma Associated 1 RNA, Human | CARBOPLATIN, CISPLATIN, GEMCITABINE, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | Phase 3 | 1,004 | 2024-04-04 | Urinary Tract Cancer | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | Phase 3 | 931 | 2018-04-11 | Bladder Cancer | ATEZOLIZUMAB, DOCETAXEL, PACLITAXEL, VINFLUNINE | Its record names the disease | ClinicalTrials.gov |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection | Phase 3 | 809 | 2020-11-18 | Carcinoma, Transitional Cell | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03390504 | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | Phase 3 | 629 | 2025-05-14 | Urothelial Cancer | ERDAFITINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | Phase 1/2 | 557 | 2023-03-13 | Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer | BEMPEGALDESLEUKIN, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | Phase 3 | 530 | 2019-03-08 | Urothelial Carcinoma | DOCETAXEL, RAMUCIRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase 1/2 | 515 | 2021-04-06 | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | SACITUZUMAB GOVITECAN | Its record names the disease | ClinicalTrials.gov |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Phase 3 | 506 | 2020-02-17 | Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma | BEVACIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | Phase 3 | 505 | 2023-10-31 | Urothelial Carcinoma | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Phase 1/2 | 407 | 2024-03-20 | Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer | FUTIBATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02501096 | A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | Phase 1/2 | 357 | 2023-07-20 | Tumors | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02387996 | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | Phase 2 | 270 | 2017-05-24 | Various Advanced Cancer | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Phase 2 | 263 | 2023-03-24 | UC (Urothelial Cancer) | PEMIGATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03606174 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | Phase 2 | 260 | 2023-08-24 | Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra | ENFORTUMAB VEDOTIN, NIVOLUMAB, PEMBROLIZUMAB, SITRAVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | Phase 2 | 200 | 2017-11-14 | Bladder Cancer, Urothelial Carcinoma | APATORSEN, DOCETAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | 175 | 2021-12-29 | Carcinoma, Transitional Cell | ROGARATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | Phase 1 | 168 | 2020-04-28 | Neoplasms | ROGARATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03459846 | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) | Phase 2 | 154 | 2022-10-26 | Urinary Bladder Neoplasms | DURVALUMAB, OLAPARIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0040679/trials